

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number 09/417,479
 Filing Date October 13, 1999
 First Named Inventor McCafferty
 Group Art Unit 1627
 Examiner Name P. Ponnaluri
 Attorney Docket Number 213839-00011

TECH CENTER 1600/2900

AUG 04 2003

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
JL	A1	US-6,331,415	12-18-2001	Cabilly et al.	
JL	A2	US patent application 07/240,160	03-22-1990	Ladner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
JL	B1	WO 88/01649	03-10-1988	Ladner et al.		
	B2	GB9022845.3	10-19-1990	Medical Research Council		
	B3	GB9024503.6 patent application	11-12-1990	O'Brien		
	B4	GB 9104744.9 patent application	03-06-1991	O'Brien		
	B5	EP-A-0 368 684	05-16-1990	Winter		
	B6	GB9015198.6 priority document	07-10-1990	O'Brien		
	B7	GB 9022845.3 priority document	10-19-1990	Medical Research Council		
	B8	GB 9104744.9 priority document	03-06-1991	O'Brien		
	B9	GB9110549.4 priority document	05-15-1991	O'Brien		
	B10	EP-B-0 349 578 B1	11-30-1994	Ladner et al.		


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/417,479
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
Sheet	2	of	8
		Attorney Docket Number	213839-00011

RECEIVED
 A111 0 4 2003
 TECH CENTER 160012800

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JL	C1	Interlocutory Decision in Opposition Proceedings to the European Patent EP-B-0589877 dated April 15, 2002 (reference number SMW/CP9503921)	
	C2	Notice of Appeal to the European Patent EP-B-0589877 from Dyax Corp., filed June 17, 2002	
	C3	Communication from EPO on Notice of Appeal filed by Dyax, issued October 21, 2002	
	C4	Notice of Appeal to the European Patent EP-B-0589877 from BioInvent Therapeutic AB, filed June 14, 2002	
	C5	Appeal No. T0639/02-334 from BioInvent Therapeutic AB to the European Patent EP-B-0589877, filed August 22, 2002	
	C6	Notice of Appeal to the European Patent EP-B-0589877 from MorphoSys AG, filed June 20, 2002, and Grounds of the Appeal, filed August 22, 2002	
	C7	Notice of Appeal, filed June 24, 2002, and Grounds of Appeal, filed August 22, 2002, from Cambridge Antibody Technology Limited against the Decision of the Opposition Division	
	C8	Notice of Opposition to the European Patent EP-B-0589877 from BioInvent International AB, filed October 24, 2002	
	C9	Document D80 in Appeal No. T0639/02-334: HHS' Freedom of Information Act (FOIA) regulations: table of contents, 5.1, 5.2, 5.3, 5.5, 5.21, 5.22, 5.24, 5.31, 5.32, 5.33, 5.34, 5.35, 5.51, 5.61 and 5.65	
	C10	Document D81 in Appeal No. T0639/02-334: Smith Declaration	
	C11	Document D82 in Appeal No. T0639/02-334: Copy of Grant Application GM 41478 and renewal applications supplied by the DHH	
↓	C12	Document D83 in Appeal No. T0639/02-334: Letter, dated August 26, 1999, from Cambridge Antibody Technology Ltd in opposition proceedings against EP 0 527 839	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents as www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	3	of	8	Complete if Known Application Number 09/417,479 Filing Date October 13, 1999 First Named Inventor McCafferty Group Art Unit 1627 Examiner Name P. Ponnaluri Attorney Docket Number 213839-00011
-------	---	----	---	--


JL	C13	Document D85 in Appeal No. T0639/02-334: Proprietor's letter of November 12, 1997, and amended claims	
	C14	Document D86 in Appeal No. T0639/02-334: EP 0774 511 A1	
	C15	Document D87 in Appeal No. T0639/02-334: Proprietor's letter of November 15, 2000	
	C16	Document D88 in Appeal No. T0639/02-334: Grounds of Appeal, dated August 22, 2002, from present opponent in opposition proceedings against EP 0589 877	
	C17	Document D89 in Appeal No. T0639/02-334: OD's Written Interlocutory Decision in opposition proceedings against EP 0 589 877	
	C18	Document D90 in Appeal No. T0639/02-334: Marvin & Hohn (1969). Bacteriological Rev 33(2), 172-209	
	C19	Notice of Opposition to the European Patent EP-B-0589877 from Crucell Holland B.V., filed October 30, 2002	
	C20	Document D13: Communication of the European Office of June 28, 2001	
	C21	Document D27: Details of Smith Grant application and second and third year renewals thereof as provided by the DHHS in response to a Freedom to Information Act (FOIA) request	
	C22	Notice of Opposition to the European Patent EP-B-0589877 from Dyax Corp.	
	C23	Document D1: EPO register print-out for the patent application with file history information	
	C24	Document D3: Claims filed with the divisional application	
	C25	Document D7: Pluckthun and Skerra, "Expression of functional antibody Fv and Fab fragments in <i>Escherichia coli</i> ", <i>Methods in Enzymology</i> , Vol. 178: 497-515 (1989)	
	C26	Notice of Opposition to the European Patent EP-B-0589877 from MorphoSys, filed October 30, 2002	
✓	C27	Document D1: Genentech, US Patent Application 07/621,667, priority document to EP 92902109.5	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.


Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

TECH CENTER 1600 2900
AUG 01 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/417,479
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
Attorney Docket Number	213839-00011		
Sheet	4	of	8

RECEIVED

JL	C28	Opposition to European patent EP-B-0589877, cited opposition document D2: Nelson et al. "Filamentous phage DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III", <i>Virology</i> 108: 338-350 (1981)	
	C29	Opposition to European patent EP-B-0589877, cited opposition document D3: McCoy and Khorana "Introduction and characterization of amber mutations in the bacteriorhodopsin gene", <i>J. Bio. Chem.</i> 258: 8456-8461 (1983)	
	C30	Opposition to European patent EP-B-0589877, cited opposition document D5: Bullock et al. "XL1-blue: a high efficiency plasmid transforming <i>recA</i> Escherichia coli strain with beta-galactosidase selection", <i>Bio Techniques</i> 5: 376-378 (1987)	
	C31	Opposition to European patent EP-B-0589877, cited opposition document D6: Schnee et al. "Construction and expression of a recombinant antibody-targeted plasminogen activator", <i>Proc. Natl. Acad. Sci. USA</i> 84:6904-6908 (1987)	
	C32	Opposition to European patent EP-B-0589877, cited opposition document D15: Parmley and Smith "Filamentous fusion phage cloning vectors for the study of epitopes and design of vaccines", <i>Adv. Exp. Med. Biol.</i> 251: 215-218 (1989)	
	C33	Opposition to European patent EP-B-0589877, cited opposition document D18: Chaudhary et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", <i>Nature</i> 339: 394-397 (1989)	
	C34	Opposition to European patent EP-B-0589877, cited opposition document D26: Scott and Smith "Searching for peptide ligands with an epitope library", <i>Science</i> 249: 386-389 (1990)	
↓	C35	Opposition to European patent EP-B-0589877, cited opposition document D27: Devlin et al. "Random peptide libraries: a source of specific protein binding molecules", <i>Science</i> 249: 404-405 (1990)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	09/417,479
Filing Date	October 13, 1999
First Named Inventor	McCafferty
Group Art Unit	1627
Examiner Name	P. Ponnaluri
Attorney Docket Number	213839-00011


JL	C36	Opposition to European patent EP-B-0589877, cited opposition document D37: Markland et al. "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13", <i>Gene</i> 109: 13-19 (1991)	
	C37	Opposition to European patent EP-B-0589877, cited opposition document D38: Roberts et al. "Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage", <i>Proc. Natl. Acad. Sci. USA</i> 89: 2429-2433 (1992)	
	C38	Opposition to European patent EP-B-0589877, cited opposition document D39: Glockshuber et al. "The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in escherichia coli", <i>Biochemistry</i> 31: 1270-1279 (1992)	
	C39	Opposition to European patent EP-B-0589877, cited opposition document D41: Kay et al. "Phage display of peptides and proteins", A Laboratory Manual (1996)	
	C40	Opposition to European patent EP-B-0589877, cited opposition document D42: Proba et al. "A natural antibody missing a cysteine in Vh: consequences for thermodynamic stability and folding", <i>J. Mol. Biol.</i> 265: 161-172 (1997)	
	C41	Opposition to European patent EP-B-0589877, cited opposition document D43: Proba et al. "Antibody scFv fragments without disulfate bonds made by molecular evolution", <i>J. Mol. Biol.</i> 275: 245-253 (1998)	
	C42	Opposition to European patent EP-B-0589877, cited opposition document D44: Letter of 18 November 1992 to EPO in prosecution of EP-B-0 349 578	
	C43	Opposition to European patent EP-B-0589877, cited opposition document D45: Page 3 of EPO letter of 19 October 1993 in prosecution of EP-B-0 768 377	
✓	C44	Opposition to European patent EP-B-0589877, cited opposition document D46: Letter of 22 September 1994 to EPO in prosecution of EP-B-0 768 377	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

TECH CENTER 1500/2900
AUG 04 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/417,479
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
Sheet 6 of 8	Attorney Docket Number	213839-00011	

JL	C45	Opposition to European patent EP-B-0589877, cited opposition document D47: Extract from OD Decision in opposition proceedings against EP-B-0 201 184, 1995	
	C46	Opposition to European patent EP-B-0589877, cited opposition document D48: Letter of 14 February 1996 to EPO in prosecution of EP-A-0 527 839	
	C47	Opposition to European patent EP-B-0589877, cited opposition document D49: the Boards of Appeal of the European Patent Office decision of 8 May 1996, case number T694/92 – 3.3.4	
	C48	Opposition to European patent EP-B-0589877, cited opposition document D50: Extract from opposition proceeding against EP-B-0 349 578 (1996)	
	C49	Opposition to European patent EP-B-0589877, cited opposition document D51: Extract from OD Decision in proceedings against EP-B-0 349 578 (1998)	
	C50	Opposition to European patent EP-B-0589877, cited opposition document D53: Declaration of professor sir Aaron Klug, Ph.D. with exhibits, (23 June 1998)	
	C51	Opposition to European patent EP-B-0589877, cited opposition document D54: Scott preprint, date of availability to public unproven.	
	C52	Opposition to European patent EP-B-0589877, cited opposition document D55: Smith grant application, date of availability to public unproven.	
	C53	Opposition to European patent EP-B-0589877, late filed document D56: claim for infringement of 24 September 1998	
	C54	Opposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Constrained peptide libraries as a tool for finding mimotopes", <i>Gene</i> 151: 115-118 (1994).	
↓	C55	Opposition to European patent EP-B-0589877, late filed document D59: two chapters of "Lambda II" (eds. Hendrix et al.) Cold Spring Harbour Laboratory, Cold Spring Harbour, New York, 1998: "A Beginner's Guide to Lambda Biology" (Arber) and "Tail Assembly and Injection" (Katsura)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/417,479
		Filing Date	October 13, 1999
		First Named Inventor	McCafferty
		Group Art Unit	1627
		Examiner Name	P. Ponnaluri
		Attorney Docket Number	213839-00011
Sheet	7	of	8

JL	C56	Opposition to European patent EP-B-0589877, late filed document D60: Parmley & Smith " Filamentous fusion phage cloning vectors for the study of epitopes and design vaccines ", <i>Adv. Exp. Med. Biol.</i> 251: 251-8 (1989). The document was not admitted to the proceedings.	
	C57	Opposition to European patent EP-B-0589877, late filed document D63: Declaration of William D. Huse, MD, Ph.D. (17 August 1999). The document was not admitted to the proceedings.	
	C58	Opposition to European patent EP-B-0589877, late filed document D66: Crissman & Smith, " Gene-III protein of filamentous phages: evidence for a carboxyl-terminal domain with a role in morphogenesis ", <i>Virology</i> 132: 445-455 (1994).	
	C59	Opposition to European patent EP-B-0589877, late filed document D67: Declaration of Dr. Viia Valge-Archer (3 May, 2000)	
	C60	Opposition to European patent EP-B-0589877, late filed document D68: Declaration of Dr. Hiroshi Ueda (3 May, 2000)	
	C61	Opposition to European patent EP-B-0589877, late filed document D69: First Declaration of Dr. Rachel B. Kent (4 February, 2000). The document was objected to by patentees.	
	C62	Opposition to European patent EP-B-0589877, late filed document D71: letter of patentees filed at USPTO on 16 July 1996 . The document was objected to by patentees.	
	C63	Opposition to European patent EP-B-0589877, late filed document D72: letter of patentees filed at USPTO on 6 March 1997 . The document was objected to by patentees.	
	C64	Opposition to European patent EP-B-0589877, late filed document D73: Opposition by CAT against EP-B-0 564 531 . The document was objected to by patentees.	
✓	C65	Opposition to European patent EP-B-0589877, late filed document D74: Decision of EPOD on EP-B-0 201 184 . The document was objected to by patentees.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

Complete if Known

Application Number	09/417,479
Filing Date	October 13, 1999
First Named Inventor	McCafferty
Group Art Unit	1627
Examiner Name	P. Ponnaluri
Attorney Docket Number	213839-00011

JL	C66	Opposition to European patent EP-B-0589877, late filed document D75: Declaration of Prof. Andreas Plückhun. The document was objected to by patentees.	
	C67	Opposition to European patent EP-B-0589877, late filed document D76: Notice of grant awarded to Smith grant application. The document was objected to by patentees.	
	C68	Opposition to European patent EP-B-0589877, late filed document D77: Endemann and Model "Location of filamentous phage minor coat proteins in phage and in infected cells", J. Mol. Biol. 250: 496-506 (1995). The document was objected to by patentees.	
	C69	Opposition to European patent EP-B-0589877, late filed document D79: Extract from MorphoSys website.	
	C70	Opposition to European patent EP-B-0589877, late filed document D80: Written Decision dated 26 May 2000 to revoke EP-B-0436597.	
	C71	Opposition to European patent EP-B-0589877, late filed document D81: 2nd Declaration of Dr. Viia Valge-Archer (31 May, 2000).	

Examiner Signature	/Jeffrey Lundgren/	Date Considered	05/01/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)										Docket Number 213839-00011			Application Number 09/417,479								
										Applicant McCafferty <i>et al.</i>											
										Filing Date October 13, 1999			Group Art Unit 1627								
U. S. PATENT DOCUMENTS																					
EXAMINER INITIAL		DOCUMENT NUMBER							DATE		NAME				CLASS		SUB CLASS		FILING DATE IF APPROP.		
JL		1	6	3	3	1	4	1	5			Cabilly <i>et al.</i>				435		69.6		6/10/88	
FOREIGN PATENT DOCUMENTS																					
		DOCUMENT NUMBER							DATE		COUNTRY				CLASS		SUB CLASS		Translation Yes No		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																					
JL		2		First Amended Complaint, Filed March 8, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (24 pages) (U.S. District Court, District of Columbia)(signed by John S. Skilton, Attorney for Plaintiff.)																	
		3		Cambridge Antibody Technology Limited's Answer to First Amended Complaint, Filed March 22, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia)(signed by Brian H. Corcoran, Attorney for Defendant).																	
		4		Il'ichev, A.A., <i>et al.</i> , "M13 Filamentous Bacteriophage in Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990).																	
		5		Iliychev, A.A., <i>et al.</i> , "M13 Filamentous Bacteriophage for Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990). (In Russian with Translated Abstract)																	
		6		Redacted Agreement Between Medical Research Council and Cambridge Antibody Technology Limited and Cambridge Antibody Technology Group plc, made 01 January 1997																	
		7		Deposition Transcript of David W. Clough, taken April 19, 2002 (Morphosys AG v. Cambridge Antibody Technology Limited, (U.S. District Court, Northern District of Illinois, Eastern Division).																	
		8		E.I. du Pont de Nemours v. Cetus Corp., 19 USPQ2d 1174, (DC N.Cal. 1990).																	
V		9		OddzOn Products Inc. v. Just Toys Inc., 43 USPQ2d 1641(CAFC 1997).																	
EXAMINER													DATE CONSIDERED								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.																					

RECEIVED

OCT 22 2002

TECH CENTER 1600/2000

RECEIVED

OCT 22 2002

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to provide information unless it contains a valid OMB control number.

TEC-ENTER 1000/2900

Sheet 2 of 3

Substitute for form 1449A/PTO				Docket Number 213839-00011		Application Number 09/417,479		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant McCafferty <i>et al.</i>				
				Filing Date October 13, 1999		Group Art Unit 1627		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER				DATE	NAME	CLASS SUB CLASS	FILING DATE IF APPROP.
FOREIGN PATENT DOCUMENTS								
	DOCUMENT NUMBER				DATE	COUNTRY	CLASS SUB CLASS	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
JL	10	Deposition Transcript of George P. Smith, Ph.D., taken 14 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)						
	11	Deposition Transcript of Dr. David Chiswell, taken 29 April 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)						
	12	Deposition Transcript of Dr. Gregory Paul Winter, taken April 30, 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)						
	13	Vol. I - Deposition Transcript of Sean Malcolm Walton, taken 01 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)						
	14	Vol. II - Deposition Transcript of Sean Malcolm Walton, taken 02 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)						
	15	Chiswell memo, dated 30 July 1990, transmitting a copy of the Collaborative Agreement between Cambridge Antibody Technology and The Medical Research Council, dated July 27, 1995.						
V	16	Declaration of George P. Smith, Ph.D., Under 37 C.F.R. § 1.132, executed 30 June 1995 (submitted during the prosecution of U.S. Application No. 08/322,352):						
V	17	Declaration of Brian K. Kay, Ph.D., executed 28 June 1998, (submitted during the prosecution of European Appln. No. 91913039.3)						
EXAMINER							DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								

RECEIVED

OCT 22 2002

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 3 of 3

Substitute for form 1449A/PTO				Docket Number 213839-00011		Application Number 09/417,479	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant McCafferty et al.			
				Filing Date October 13, 1999		Group Art Unit 1627	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS	SUB CLASS
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUB CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
JL	18	Abstract of George P. Smith, Grant No. 1R01GM41478-01A1, Project Start Date: July 1, 1989.					
	19	Smith Grant Application, entitled: "Filamentous Phage Physiology", dated November 1, 1988					
	20	Administration Agreement between Cambridge Antibody Technology Ltd. and Medical Research Council, dated 01 August 1991 (Redacted).					
	21	Fax from John McCafferty (of Cambridge Antibody Technology Limited) to Sean Walton (of Mewburn Ellis) regarding the Smith grant application.					
	22	E-mail message from John McCafferty (of Cambridge Antibody Technology Limited) to Brian Kay regarding the Smith grant application					
	23	Letter to Craig Panner (of the Academic Press) from John McCafferty (Cambridge Antibody Technology Limited) regarding the Smith grant application					
	24	Fax to John McCafferty, Ph.D. (of Cambridge Antibody Technology Limited) from Craig Panner (of Academic Press) dated June 10, 1996.					
	25	Smith, G.-P., "1988--A Year of Discovery", <i>Phage Display of Peptides and Proteins</i> , Academic Press, Inc. (1996), pp. xvii-xix.					
V	26	Northern Telecom Inc. v. Datapoint Corp., 15 USPQ 1321., (CAFC 1990).					
EXAMINER /Jeffrey Lundgren/					DATE CONSIDERED 05/01/2006		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

NOV 08 2000

SHEET 1 of 1

Supplemental Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
128111932729CSerial No.
09/417,479**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant
McCafferty et al.Filing Date
October 13, 1999Group
1627**RECEIVED**

NOV 14 2000

TECH CENTER 1603/2900

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
JL	A17	5,985,588	11/16/99	Breitling et al.	435	7.8	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER

/Jeffrey Lundgren/

DATE CONSIDERED 05/01/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAny. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
JL	A1	4,593,002	06/03/86	Dulbecco	435	172.3	
	A2	4,816,397	03/28/89	Boss <i>et al.</i>	435	68	
	A3	4,946,778	08/07/90	Ladner <i>et al.</i>	435	69.6	
	A4	5,091,513	02/25/92	Huston <i>et al.</i>	530	387	
	A5	5,223,409	06/29/93	Ladner <i>et al.</i>	435	69.7	
	A6	5,403,484	04/04/95	Ladner <i>et al.</i>	435	235.1	
	A7	5,427,908	06/27/95	Dower <i>et al.</i>	435	5	
	A8	5,658,727	08/19/97	Barbas <i>et al.</i>	435	6	
	A9	5,688,666	11/18/97	Bass <i>et al.</i>	435	69.4	
	A10	5,750,373	05/12/98	Garrard <i>et al.</i>	435	69.4	
	A11	5,759,817	06/02/98	Barbas, C.	435	69.7	
	A12	5,770,356	06/23/98	Light <i>et al.</i>	435	5	
	A13	5,780,279	07/14/98	Matthews <i>et al.</i>	435	172.3	
	A14	5,821,047	10/13/98	Garrard <i>et al.</i>	435	5	
	A15	5,846,765	12/08/98	Matthews <i>et al.</i>	435	69.1	
	A16	5,849,500	12/15/98	Breitling <i>et al.</i>	435		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**Applicant
McCafferty, J. et al.Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)


FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
JL *	B1	WO 83/02393	07/21/83	WIPO				
	B2	EP 2 137 631	10/10/84	EP				
	B3	EP 0 168 933	01/22/86	EP				
	B4	WO 88/06630	09/07/88	WIPO				
	B5	WO 88/09344	12/01/88	WIPO				
	B6	EP 0 324 162 A1	12/24/88	EP				
	B7	AU-B-27617/88	07/06/89	AU				
	B8	WO 90/02809	03/22/90	WIPO				
	B9	WO 90/05144	05/17/90	WIPO				
	B10	WO 90/14424	11/29/90	WIPO				
	B11	WO 90/14430	11/29/90	WIPO				
	B12	WO 90/14443	11/29/90	WIPO				
	B13	WO 91/10737	07/25/91	WIPO				
	B14	WO 91/17271	11/14/91	WIPO				
	B15	WO 92/06204	04/16/92	WIPO				
↓	B16	WO 92/09690	06/11/92	WIPO				
	B17	WO 92/18619	10/29/92	WIPO				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAny. Docket No.
28111/32729CSerial No.
09/417,479

INFORMATION DISCLOSURE STATEMENT

Applicant
McCafferty, J. et al.Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C1	Amit, A.G. et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (August, 1986).
	C2	Armstrong, J. et al., "Domain Structure of Bacteriophage fd Adsorption Protein," <i>FEBS Lett.</i> , 135(1):167-172 (November, 1981).
	C3	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties," <i>Proteins: Structure, Function and Genetics</i> , 8:309-314 (1990).
	C4	Beck, E. et al., "Nucleotide sequence and genome organisation of filamentous bacteriophages f1 and fd," <i>Gene</i> , 16:35-58 (1981).
	C5	Beck, E. et al., "Nucleotide sequence of bacteriophage fd DNA," <i>Nucleic Acids Research</i> , 5(12):4495-4503 (1978).
	C6	Berek, C. et al., "Molecular events during maturation of the immune response to oxazolone," <i>Nature</i> , 316:412-418 (August, 1985).
	C7	Better, M. et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," <i>Science</i> , 240:1041-1043 (May, 1988).
	C8	Bhat, T.N. et al., "Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding," <i>Nature</i> , 347:483-485 (October, 1990).
	C9	Bird, R.E. et al., "Single chain antibody variable regions," <i>TIBTECH</i> , 9:132-137 (April, 1991).
	C10	Bird, R.E. et al., "Single-Chain Antigen-Binding Proteins," <i>Science</i> , 242:423-426 (October, 1988).
	C11	Boeke, J.D. et al., "Effects of Bacteriophage f1 Gene III Protein on the Host Cell Membrane," <i>Mol. Gen. Genet.</i> , 186:185-192 (1982).
	C12	Boyle, W., "An Extension of the ⁵¹ Cr-Release Assay for the Estimation of Mouse Cytotoxins," <i>Transplantation</i> , 6(6):761-764 (1968).
	C13	Branden, C. et al., in <i>Introduction to Protein Structure</i> , Garland Publishing, Inc., New York and London, pp.26-29 (1991).
✓	C14	Brenna, O. et al., "Affinity-Chromatography Purification of Alkaline Phosphatase from Calf Intestine," <i>Biochem. J.</i> , 151:291-296 (1975).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAny. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C15	Brownstone, A. <i>et al.</i> , "Biological Studies with an Iodine-Containing Synthetic Immunological Determinant 4-Hydroxy-3-iodo-5-nitrophenylacetic Acid (NIP) and Related Compounds," <i>Immunology</i> , 10:481-492 (1966)
	C16	Brownstone, A. <i>et al.</i> , "Chemical and Serological Studies with an Iodine-Containing Synthetic Immunological Determinant 4-Hydroxy-3-iodo-5-nitrophenylacetic Acid (NIP) and Related Compounds," <i>Immunology</i> , 10:465-479 (1966).
	C17	Carter, P. <i>et al.</i> , "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <i>Nucl. Acids Res.</i> , 13(12):4431-4443 (1985).
	C18	Casali, P. <i>et al.</i> , "Human Monoclonals from Antigen-Specific Selection of B Lymphocytes and Transformation by EBV," <i>Science</i> , 234:476-479 (October, 1986).
	C19	Chaidaroglou, A. <i>et al.</i> , "Function of Arginine-166 in the Active Site of <i>Escherichia coli</i> Alakaline Phosphatase," <i>Biochemistry</i> , 27:8338-8343 (1988).
	C20	Chang, C. N. <i>et al.</i> , "Nuceotide sequence of the alkaline phosphatase gene of <i>Escherichia coli</i> ," <i>Gene</i> , 44:121-125 (1986).
	C21	Chaudhary, V.K. <i>et al.</i> , "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci., USA</i> , 87:1066-1070 (February, 1990).
	C22	Chiang, Y.L. <i>et al.</i> , "Direct cDNA Cloning of the Rearranged Immunoglobulin Variable Region," <i>BioTechniques</i> , 7(4):360-366 (1989).
	C23	Choo, Y. <i>et al.</i> , "In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence," <i>Nature</i> , 372:642-645 (1994).
	C24	Choo, Y. <i>et al.</i> , "Selection of DNA binding sites for zinc fingers using rationally randomized DNA reveals coded interactions," <i>Proc. Natl. Acad. Sci., USA</i> , 91:11168-11172 (1994).
	C25	Choo Y. <i>et al.</i> , "Toward a code for the interactions of zinc fingers with DNA: Selection of randomized fingers displayed on phage," <i>Proc. Natl. Acad. Sci., USA</i> , 91:11163-11167 (1994).
✓	C26	Chothia, C. <i>et al.</i> , "Canonical Structures for the Hypervariable Regions of Immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeApp. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


JL	C27	Chuchana, P. <i>et al.</i> , "Definition of the human immunoglobulin variable lambda (IGLV) gene subgroups," <i>Eur. J. Immunol.</i> , 20:1317-1325 (1990).
	C28	Clackson, T. <i>et al.</i> , "'Sticky feet'-directed mutagenesis and its application to swapping antibody domains," <i>Nucl. Acids Res.</i> , 17(24):10163-10170 (1989).
	C29	Cunningham, C. <i>et al.</i> , "Antibody engineering - how to be human," <i>Trends Biotechnology</i> , 10(4):112-113 (April, 1992).
	C30	Curti, B.D., "Physical Barriers to drug delivery in tumors," <i>Critical Reviews in Oncology/Hematology</i> , 14:29-39 (1993).
	C31	Cwirla, S.E. <i>et al.</i> , "Peptides on phage: A vast library of peptides for identifying ligands," <i>Proc. Natl. Acad. Sci., USA</i> , 87:6378-6382 (1990).
	C32	De Bellis, D. <i>et al.</i> , "Regulated expression of foreign genes fused to <i>lac</i> : control by glucose levels in growth medium," <i>Nucl. Acids Res.</i> , 18(5):1311 (1980).
	C33	De la Cruz <i>et al.</i> , "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <i>J. Biol. Chem.</i> , 263(9):4318-4322 (1988).
	C34	Dildrop, R., "A new classification of mouse V _H sequences," <i>Immunol. Today</i> , 5(4):85-86 (1984).
	C35	Dillman, R.O., "Monoclonal Antibodies for Treating Cancer," <i>Annals of Internal Medicine</i> , 111:592-603 (1989).
	C36	Dower, W.J. <i>et al.</i> , "High efficiency transformation of <i>E. coli</i> by high voltage electroporation," <i>Nucl. Acids Res.</i> , 16(13):6127-6145 (1988).
	C37	Eckert, K.A. <i>et al.</i> , "High fidelity DNA synthesis by the <i>Thermus aquaticus</i> DNA polymerase," <i>Nucl. Acids Res.</i> , 18(13):3739-3744 (1990).
	C38	Eisen, H.N., "Determination of Antibody Affinity For Haptens and Antigens by Means of Fluorescence Quenching," <i>Meth. Med. Res.</i> , 10:115-121 (1964).
	C39	Evan, G.I. <i>et al.</i> , "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product," <i>Mol. Cell. Biol.</i> , 5(12):3610-3616 (December, 1985).
↓	C40	Fikes, J.D. <i>et al.</i> , "Maturation of <i>Escherichia coli</i> Maltose-binding Protein by Signal Peptidase I <i>in Vivo</i> ," <i>J. Biological Chemistry</i> , 265(6):3417-3423 (1990).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28111/32729CSerial No.
09/417,479

INFORMATION DISCLOSURE STATEMENT

Applicant
McCafferty, J. et al.Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C41	Galfrè, G. et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods Enzymology</i> , 73:3-46 (1981).
	C42	Gherardi, E. et al., "A single-step procedure for cloning and selection of antibody-secreting hybridomas," <i>J. Immunol. Methods</i> , 126:61-68 (1990).
	C43	Glockshuber, R. et al., "The Disulfide Bonds in Antibody Variable Domains: Effects on Stability, Folding in Vitro, and Functional Expression in Escherichia coli," <i>Biochemistry</i> , 31:1270-1279 (1992).
	C44	Goldstein, G., "Overview of the Development of ORTHOCLONE OKT3: Monoclonal Antibody for Therapeutic Use in Transplantation," <i>Transplantation Proceedings</i> , Vol. XIX, No. 2, Suppl. 1:1-6 (April, 1987).
	C45	Gorick, B.D. et al., "Three Epitopes on the Human Rh Antigen D Recognized by ¹²⁵ I-Labelled Human Monoclonal IgG Antibodies," <i>Vox. Sang.</i> , 55:165-170 (1988).
	C46	Gottesman, M.E. et al., "Transcription Antitermination by Bacteriophage Lambda N Gene Product," <i>J. Mol. Biol.</i> , 140:57-75 (1980).
	C47	Grant, R.A. et al., "Structure of the Filamentous Bacteriophage f1," <i>J. Biol. Chem.</i> , 256(1):539-546 (January, 1981).
	C48	Griffiths, G.M. et al., "Somatic mutation and the maturation of immune response to 2-phenyl oxazolone," <i>Nature</i> , 312:271-275 (1984).
	C49	Gronwald, R.G.K. et al., "Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: Evidence for more than one receptor class," <i>Proc. Natl. Acad. Sci., USA</i> , 85:3435-3439 (May, 1988).
	C50	Harper, M. et al., "Antigen Specificity and Cross-Reactivity of Monoclonal Anti-Lysozyme Antibodies," <i>Molec. Immunol.</i> , 24(2):97-108 (1987).
	C51	Harris, W.J. et al., "Therapeutic antibodies - the coming of age," <i>Trends Biotechnology</i> , 11:42-44 (February, 1993).
	C52	Hird, V. et al., "Immunotherapy with Monoclonal Antibodies," in <i>Genes and Cancer</i> , Edited by D. Carney and K. Sikora, John Wiley & Sons, Ltd., pp.183-189 (1990).
↓	C53	Horton, R.M. et al., "Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension," <i>Gene</i> , 77:61-68 (1989).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeApp. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C54	Hughes-Jones, N.C. <i>et al.</i> , "Nucleotide sequences and three-dimensional modelling of the V _H and V _L domains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system," <i>Biochem. J.</i> , 268:135-140 (1990).
	C55	Hull, W.E. <i>et al.</i> , " ³¹ P Nuclear Magnetic Resonance Study of Alkaline Phosphatase: The Role of Inorganic Phosphate in Limiting the Enzyme Turnover Rate at Alkaline pH," <i>Biochemistry</i> , 15(7):1547-1561 (1976).
	C56	Huse <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 246:1275-1281 (1989).
	C57	Huston, J.S. <i>et al.</i> , "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci., USA</i> , 85:5879-5883 (August, 1988).
	C58	Izard, J.W. <i>et al.</i> , "Signal peptides: exquisitely designed transport promoters," <i>Molecular Microbiology</i> , 13(5):765-773 (1994).
	C59	Kabat <i>et al.</i> , <i>Sequences of Proteins of Immunological Interest</i> , 5th ed. pgs.339, 362, 430, 451 and 1418 (1991).
	C60	Kabat <i>et al.</i> , <i>Sequences of Proteins of Immunological Interest</i> , 4th ed. p.181 (1987).
	C61	Kang, A.S. <i>et al.</i> , "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <i>Proc. Natl. Acad. Sci., USA</i> , 88(24):1120-11123 (1991).
	C62	Kang, A.S. <i>et al.</i> , "Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces," <i>Proc. Natl. Acad. Sci., USA</i> , 88(10):4363-4366 (1991).
	C63	Kettleborough, C.A. <i>et al.</i> , "Humanization of a mouse antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> , 4(7):773-783 (1991).
	C64	Kim, Y. <i>et al.</i> , "Refinement of Eco RI Endonuclease Crystal Structure: A Revised Protein Chain Tracing," <i>Science</i> , 249:1307-1309 (1990).
	C65	Köhler, G. <i>et al.</i> , "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256:495-497 (August, 1975).
✓	C66	Kornberg, A., <i>DNA Replication</i> , W.H. Freeman & Co., San Francisco, pp. 15, 20, 287, 385, 368-369, 383-385, 393, 461, 474, 478-496, 505-506 (1974).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeApp. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C67	Laforet, G.A. <i>et al.</i> , "Functional Limits of Conformation, Hydrophobicity, and Steric Constraints in Prokaryotic Signal Peptide Cleavage Regions," <i>J. Biological Chemistry</i> , 266(2):1326-1334 (1991).
	C68	Larrick, J.W. <i>et al.</i> , "Rapid Cloning of Rearranged Immunoglobulin Genes from Human Hybridoma Cells Using Mixed Primers and the Polymerase Chain Reaction," <i>Biochem. Biophys. Res. Commun.</i> , 160(3):1250-1255 (May, 1989).
	C69	Lesk, A. M. <i>et al.</i> , "Elbow motion in the immunoglobulins involves a molecular ball-and-socket joint," <i>Nature</i> , 335:188-190 (September, 1988).
	C70	Mäkelä, O. <i>et al.</i> , "Inheritance of Antibody Specificity V Anti-2-Phenyloxazolone in the Mouse," <i>J. Exp. Med.</i> , 148:1644-1660 (December, 1978).
	C71	Malamy, M.H. <i>et al.</i> , "Purification and Crystallization of the Alkaline Phosphatase of <i>Escherichia coli</i> ," <i>Biochemistry</i> , 3(12):1893-1897 (December, 1964).
	C72	Marvin, D.A. <i>et al.</i> , "Molecular Models and Structural Comparisons of Native and Mutant Class I Filamentous Bacteriophages Ff m(fd, f1, M13), If1 and IKe," <i>J. Mol. Biol.</i> , 235:260-286 (1994).
	C73	McCafferty <i>et al.</i> , "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> , 348:552-554 (1990).
	C74	McCracken, S. <i>et al.</i> , "Functional and Structural Properties of Immobilized Subunits of <i>Escherichia coli</i> Alkaline Phosphatase," <i>J. Biol. Chem.</i> , 255(6):2396-2404 (March, 1980).
	C75	Melamed, M.D. <i>et al.</i> , "Requirements for the establishment of heterohybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen," <i>J. Immunological Methods</i> , 104:245-251 (1987).
	C76	Milstein F.R.S., C., "The Croonian Lecture, 1989 Antibodies: a paradigm for the biology of molecular recognition," <i>Proceedings of the Royal Society of London</i> , 239(1294):1-16 (1990)
V	C77	Munro, S. <i>et al.</i> , "An Hsp70-like Protein in the ER: Identity with the 78 kd Glucose-Regulated Protein and Immunoglobulin Heavy Chain Binding Protein," <i>Cell</i> , 46:291-300 (July, 1986).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAny. Docket No.
28111/32729CSerial No.
09/417,479

INFORMATION DISCLOSURE STATEMENT

Applicant
McCafferty, J. et al.Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C78	Nagai, K. et al., "Synthesis and Sequence-Specific Proteolysis of Hybrid Proteins Produced in <i>Escherichia coli</i> ," <i>Methods Enzymology</i> , 153:461-481 (1987).
	C79	Neuberger, M.S. et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
	C80	Newman, A.K. et al., "DNA Sequences of Structural Genes for <i>Eco</i> RI DNA Restriction and Modification Enzymes," <i>J. Biological Chemistry</i> , 256(5):2131-2139 (1981).
	C81	Ohlson, S. et al., "Novel Approach to Affinity Chromatography Using "Weak" Monoclonal Antibodies," <i>Anal. Biochem.</i> , 169:204-208 (1988).
	C82	Oliver, D.B. et al., "Periplasm and Protein Secretion," in <i>Escherichia coli and Salmonella typhimurium: cellular and molecular biology</i> , F.C. Neidhart (ed.), American Society for Microbiology, Washington, pp. 56-69.
	C83	Orlandi, R. et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Natl. Acad. Sci., USA</i> , 86:3833-3837 (May, 1989).
	C84	Osband, M.E. et al., "Problems in the investigational study and clinical use of cancer immunotherapy," <i>Immunology Today</i> , 11(6):193-195 (1990).
	C85	Parmley et al., "Antibody-selectable Filamentous fd Phage Vectors: Affinity Purification of Target Genes," <i>Gene</i> , 73(2):305-318 (December, 1988).
	C86	Parmley, S.F. et al., "Filamentous Fusion Phage Cloning Vectors for the Study of Epitopes and Design of Vaccines," <i>Adv. Exp. Med. Biol.</i> , 251:215-218 (1989).
	C87	Perelson, A.S., "Immune Network Theory," <i>Immunol. Reviews</i> , 110:5-36 (1989).
	C88	Pratt, D. et al., "Conditional Lethal Mutants of the Small Filamentous Coliphage M13 II. Two Genes for Coat Proteins," <i>Virology</i> , 39:42-53 (1969).
	C89	Rasched, I. et al., "Ff Coliphages: Structural and Functional Relationships," <i>Microbiological Reviews</i> , 50(4):401-427 (1986).
	C90	Riechmann, L. et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 332:323-327 (March, 1988).
↓	C91	Rossomando, E.F. et al., "Studies on the Bacteriophage f1 I. Alkali-induced Disassembly of the Phage into DNA and Protein," <i>J. Mol. Biol.</i> , 36:387-399 (1968).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeApp. Docket No.
28111/32729CSerial No.
09/417,479

INFORMATION DISCLOSURE STATEMENT

Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C92	Saiki, R.K. <i>et al.</i> , "Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase," <i>Science</i> , 239:487-491 (January, 1988).
	C93	Sambrook <i>et al.</i> , Molecular Cloning: A Laboratory Manual, 4.13-4.14, 4.17-4.19, 4.46 and A.12 (1989).
	C94	Sastry, L. <i>et al.</i> , "Cloning of the immunological repertoire in <i>Escherichia coli</i> for generation of monoclonal catalytic antibodies: Construction of a heavy chain variable region-specific cDNA library," <i>Proc. Natl. Acad. Sci., USA</i> , 86:5728-5732 (August, 1989).
	C95	Schaaper, R.M. <i>et al.</i> , " <i>Escherichia coli</i> <i>mutT</i> Mutator Effect during <i>in Vitro</i> DNA Synthesis," <i>J. Biol. Chem.</i> , 262(34):16267-16270 (December, 1987).
	C96	Schapper, R.M., "Mechanisms of mutagenesis in the <i>Escherichia coli</i> mutator <i>mutD5</i> : Role of DNA mismatch repair," <i>Proc. Natl. Acad. Sci., USA</i> , 85:8126-8130 (November, 1988).
	C97	Schneider, G. <i>et al.</i> "Analysis of Cleavage-Site Patterns in Protein Precursor Sequences with a Perceptron-Type Neural Network," <i>Biochemical and Biophysical Research Communications</i> , 194(2):951-959 (1993).
	C98	Shimatake, H. <i>et al.</i> , "Purified λ regulatory protein <i>cII</i> positively activates promoters for lysogenic development," <i>Nature</i> , 292:128-132 (July, 1981).
	C99	Short <i>et al.</i> , "Lambda ZAP: A Bacteriophage Lambda Expression Vector with <i>In Vivo</i> Excision Properties," <i>Nucleic Acids Research</i> , 16(15):7583-7600 (August, 1988).
	C100	Skerra, A. <i>et al.</i> , "Assembly of a Functional Immunoglobulin F ₁ Fragment in <i>Escherichia coli</i> ," <i>Science</i> , 240:1038-1040 (May, 1988).
	C101	Smith, G.P., "Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface," <i>Science</i> , 228(4705):1315-1317 (June, 1985).
	C102	Smith, G.P., "Filamentous Phage Assembly: Morphogenetically Defective Mutants That Do Not Kill the Host," <i>Virology</i> , 167:156-165 (1988).
✓	C103	Stanfield, R.L. <i>et al.</i> , "Crystal Structures of an Antibody to a Peptide and Its Complex with Peptide Antigen at 2.8 Å," <i>Science</i> , 248:712-719 (1990).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAux. Docket No.
28111/32729CSerial No.
09/417,479

INFORMATION DISCLOSURE STATEMENT

Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


JL	C104	Stengele, I. <i>et al.</i> , "Dissection of Functional Domains in Phage fd Adsorption Protein Discrimination between Attachment and Penetration Sites," <i>J. Mol. Biol.</i> , 212(1):143-149 (1990).
	C105	Strauch, K. L. <i>et al.</i> , "An <i>Escherichia coli</i> mutation preventing degradation of abnormal periplasmic proteins," <i>Proc. Natl. Acad. Sci., USA</i> , 85:1576-1580 (March, 1988).
	C106	Tsunetsugu-Yokota <i>et al.</i> , "Expression of an Immunogenic Region of HIV by a Filamentous Bacteriophage Vector," <i>Gene</i> , 99(2):261-265 (March, 1991).
	C107	Van Wezenbeek, P. <i>et al.</i> , "Nucleotide sequence of the filamentous bacteriophage M13 DNA genome: comparison with phage fd," <i>Gene</i> , 11:129-148 (1980).
	C108	Venkitaraman, A.R., "Use of modified T7 DNA polymerase (sequence version 2.0™) for oligonucleotide site-directed mutagenesis," <i>Nucl. Acids Res.</i> , 17(8):3314 (April, 1989).
	C109	Vieira, J. <i>et al.</i> , "Production of Single-Stranded Plasmid DNA," <i>Methods Enzymol.</i> , 153:3-11 (1987).
	C110	Von Boehmer, H. <i>et al.</i> , "The Separation of Different Cell Classes from Lymphoid Organs. IX. A Simple and Rapid Method for Removal of Damaged Cells From Lymphoid Cell Suspensions," <i>J. Immunol. Methods</i> , 2:293-301 (1973).
	C111	Waldmann, T.A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (June, 1991).
	C112	Walter, G. <i>et al.</i> , "Antibodies Against Synthetic Peptides," in <i>Genetic Engineering: Principles and Methods</i> , Vol. 5, Setlow and Hollaender (eds.), Plenum, New York, pp. 61-91 (1983).
	C113	Ward, E.S. <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (October, 1989).
	C114	Webster, R.E. <i>et al.</i> , "Morphogenesis of the Filamentous Single-stranded DNA Phages," In: <i>The Single Stranded DNA Phages</i> , Cold Spring Harbor Laboratory Press, pp. 557-569 (1978).
↓	C115	White, M. R. H. <i>et al.</i> , "Imaging of Firefly Luciferase Expression in Single Mammalian Cells Using High Sensitivity Charge-Coupled Device Cameras," <i>Technique (PHILA)</i> , 2 (4) 194-201 (1990).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28111/32729CSerial No.
09/417,479**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant
McCafferty, J. *et al.*Filing Date
October 13, 1999Group
1643**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

JL	C116	Williams, A.F. <i>et al.</i> , "The Immunoglobulin Superfamily - Domains for Cell Surface Recognition ^{1,2} ," <i>Ann. Rev. Immunol.</i> , 6:381-405 (1988).
↓	C117	Winter <i>et al.</i> , "Man-made Antibodies," <i>Nature</i> , 349(6307):293-299 (January, 1991).
↓	C118	Yanisch-Perron, C. <i>et al.</i> , "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors," <i>Gene</i> , 33:103-119 (1985).
↓	C119	Zacher III, A.N. <i>et al.</i> , "A New Filamentous Phage Cloning Vector: fd-tet," <i>Gene</i> , 9:127-140 (1980).

EXAMINER /Jeffrey Lundgren/

DATE CONSIDERED 05/01/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.